# Retatrutide: Clinical Trial Record and Research Digest > Retatrutide (LY3437943) is an investigational triple-agonist in Phase 3 trials for obesity and type 2 diabetes. A measured reading of the peer-reviewed trial record. A measured reading of the peer-reviewed trial record: mechanism, Phase 2 endpoints, safety signals, and what the ongoing Phase 3 TRIUMPH program is designed to determine. ## In plain terms Retatrutide is an experimental compound developed by Eli Lilly that is currently being tested in large clinical trials for obesity and type 2 diabetes (a condition where the body does not use insulin properly). It has not been approved by any regulatory agency — not the FDA, not the EMA, nowhere — and it is not available as a prescription drug as of 2026. What makes retatrutide unusual is that it activates three different hormone receptors at the same time: GLP-1, GIP, and glucagon. Most approved drugs in this class activate only one or two. That extra glucagon arm appears to add energy-burning on top of the appetite suppression that GLP-1 drugs are known for. In the main Phase 2 trial — a rigorous 48-week study in around 338 adults — the highest tested amount produced a mean body-weight reduction of 24.2%, compared to 2.1% with placebo [1]. For a drug class, that is an unusually large number. Phase 3 trials are now underway to confirm whether those results hold at larger scale and to study long-term cardiovascular and kidney safety. This site summarizes the published research. What people report — including the side effects — is on [the effects page](/effects). ## What does retatrutide do Retatrutide simultaneously engages three class-B G-protein-coupled receptors (a family of proteins that sit in cell membranes and relay hormone signals) — the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). This triple-agonist pharmacology is engineered into a single 39-amino-acid synthetic peptide acylated with a C20 fatty-diacid chain, which anchors it to albumin in the bloodstream and extends its circulating half-life to approximately 6 days — supporting once-weekly subcutaneous dosing [4]. Cryo-electron microscopy (cryo-EM — a technique that images protein complexes at near-atomic resolution) has confirmed that retatrutide binds all three receptor complexes, with relative potency of 8.9x the native hormone at GIPR, 0.3x at GCGR, and 0.4x at GLP-1R [3]. The GIPR super-potency may explain the additive weight-loss advantage over GLP-1-only agents, while the partial GCGR agonism adds hepatic lipid mobilization and thermogenesis (heat production — the body burning stored energy) without the uncontrolled hyperglycemia associated with full glucagon activity. In a 36-week Phase 2 trial in 281 adults with type 2 diabetes, retatrutide 12 mg reduced HbA1c (glycated hemoglobin — a 3-month average of blood glucose) by -2.02% versus -0.01% with placebo, and reduced body weight by -16.94% versus -3.00% [2]. The glycemic (blood-sugar) and weight effects were dose-dependent and additive to the mechanisms of prior incretin drugs. ## How does retatrutide work The three-receptor mechanism separates into distinct layers. The GLP-1R arm slows gastric emptying, suppresses appetite through hypothalamic (brain appetite-center) signaling, and stimulates glucose-dependent insulin secretion — meaning it triggers insulin release only when blood glucose is elevated, reducing hypoglycemia risk compared to older diabetes drugs. The GIPR arm amplifies insulin secretion after meals and modulates adipose (fat) tissue metabolism; its super-potency in retatrutide may enhance the GLP-1R-mediated insulin effect while also influencing fat-cell biology directly. The GCGR arm increases energy expenditure through hepatic (liver) lipid oxidation and thermogenic (heat-generating) signaling, mobilizing stored triglycerides independently of caloric intake. This combination — appetite suppression, improved glucose control, and increased energy expenditure together — is the basis for the larger weight-loss figures observed in trials compared to dual or single-receptor agents. A 2025 review in Biomolecules characterizes the Phase 1/2 data as a step-change in pharmacological weight-loss magnitude [6]. A separate 2026 analysis found that higher retatrutide doses were associated with reductions in triglycerides and insulin-resistance biomarkers, and that changes in fatty acid oxidation (the process cells use to break down fat for fuel) accounted for 23.2% of the weight-reduction response in participants without type 2 diabetes [12]. For [Retatrutide research](/research) in greater detail, including the MASLD liver-fat data, see the full research page. ## Is retatrutide fda approved No. Retatrutide is not approved by the FDA or any other regulatory agency as of 2026. It is an investigational compound in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. The TRIUMPH trials include TRIUMPH-2 (NCT05931367), evaluating retatrutide in adults with obesity and type 2 diabetes [7]; a cardiovascular and kidney outcomes trial (NCT06383390) [8]; and an active-comparator trial directly comparing retatrutide with tirzepatide (NCT06662383) [9]. First-in-human Phase 1 work (NCT04143802) was completed in 2022 [10]. Because retatrutide is not approved, it is not available by prescription and there is no licensed formulation. Research-labeled material available through gray-market channels is unregulated, of unverified identity and purity, and carries risks the clinical trials do not — including unknown sterility, unknown concentration accuracy, and no clinical oversight. The [retatrutide results](/results) from the Phase 2 trials are summarized on this site because they are published science; that summary does not constitute an endorsement of obtaining the compound outside a trial. For [retatrutide vs tirzepatide](/vs-tirzepatide) context — including what the head-to-head Phase 3 trial is designed to determine — see the dedicated comparison page. ## Retatrutide availability and the TRIUMPH Phase 3 program Retatrutide availability for clinical use depends on regulatory approval, which requires completion of the TRIUMPH Phase 3 program and an FDA New Drug Application review. No approval timeline has been publicly committed to by Eli Lilly as of mid-2026; Phase 3 enrollment was underway across multiple trials. When will retatrutide be available as a prescription drug? The earliest plausible window, assuming Phase 3 success and an efficient FDA review, is typically 1-3 years after trial completion — placing a hypothetical approval no earlier than 2027-2028, and with no guarantee. Until approval, retatrutide is accessible only through participation in an active clinical trial. A 2025 evidence review in the World Journal of Cardiology frames triple GLP-1/GIP/glucagon agonists — including retatrutide — as representing the highest achievable weight-loss pharmacotherapy in the current literature, with cardiometabolic benefits expected from the observed biochemical changes [11]. Whether that assessment holds through the Phase 3 outcomes trials is what the ongoing work will determine. --- A measured reading of the retatrutide trial record — the Phase 2 endpoints set down and cited, the Phase 3 program noted as open, and nothing here prescribed, dispensed, or sold.